A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma

被引：5
|
作者：
Jabulowsky, Robert A.
Loquai, Carmen
Diken, Mustafa
Kranz, Lena M.
Haas, Heinrich
Attig, Sebastian
Bidmon, Nicole
Buck, Janina
Derhovanessian, Evelyne
Diekmann, Jan
Fritz, Daniel
Jahndel, Veronika
Kemmer-Brueck, Alexandra
Kuehlcke, Klaus
Kuhn, Andreas N.
Langguth, Peter
Luxemburger, Ulrich
Meng, Martin
Mueller, Felicitas
Rae, Richard
Sari, Fatih
Schwarck-Kokarakis, Doreen
Seck, Christine
Spiess, Kristina
Witt, Meike
Hassel, Jessica C.
Utikal, Jochen
Kaufmann, Roland
Kreiter, Sebastian
Huber, Christoph
Tuereci, Oezlem
Sahin, Ugur
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-CT032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT032
引用
收藏
页数：4
相关论文
共 50 条
  • [31] A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors.
    Bendell, Johanna C.
    Doi, Toshihiko
    Patel, Manish R.
    Piha-Paul, Sarina Anne
    Sen, Shiraj
    Shimizu, Toshio
    Cheng, Ben
    Mekan, Sabeen F.
    Myobatake, Yusuke
    Okuda, Yasuyuki
    Serbest, Gul
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers
    Komdeur, Fenne L.
    Singh, Amrita
    van de Wall, Stephanie
    Meulenberg, Janneke J. M.
    Boerma, Annemarie
    Hoogeboom, Baukje Nynke
    Paijens, Sterre T.
    Oyarce, Cesar
    de Bruyn, Marco
    Schuuring, Ed
    Regts, Joke
    Marra, Ruben
    Werner, Naomi
    Sluis, Jessica
    van der Zee, Ate G. J.
    Wilschut, Jan C.
    Allersma, Derk P.
    van Zanten, Coba J.
    Kosterink, Jos G. W.
    Jorritsma-Smit, Annelies
    Yigit, Refika
    Nijman, Hans W.
    Daemen, Toos
    MOLECULAR THERAPY, 2021, 29 (02) : 611 - 625
  • [33] A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer.
    Gaillard, Stephanie
    Starodub, Alexander
    O'Neil, Bert
    Mathews, Cara Amanda
    Dumbrava, Ecaterina Elena
    Friedman, Claire Frances
    Swiecicki, Paul
    Oh, Cindy
    Andreu, Celia
    Lee, Linda
    Campbell, Jacqueline
    Bowler, Timothy Geoffrey
    Drutman, Scott
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] A First-in-Human Phase I Clinical Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori Neutrophil-Activating Protein in Patients with Metastatic Breast Cancer
    Yadav, Siddhartha
    Iankov, Ianko
    Viker, Kim
    Haddad, Tufia
    Giridhar, Karthik V.
    Leon-Ferre, Roberto
    Goetz, Matthew P.
    Suman, Vera J.
    Galanis, Evanthia
    MOLECULAR THERAPY, 2023, 31 (04) : 156 - 156
  • [35] First-in-human phase I trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors
    Patnaik, A.
    Mehmi, I.
    Strauss, J.
    Xing, Y.
    Jamal, R.
    O'Neill, A.
    Lake, A. C.
    Koseoglu, S.
    Warren, M. C.
    Chung, J-K.
    Alika, A.
    Lis, R.
    Rasco, D.
    Salawu, A. T.
    Chow, W.
    Spreafico, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1435 - S1436
  • [36] Commencement of first-in-human phase I/II TCR-T clinical trial targeting shared tumor-specific hotspot mutations in solid tumors
    Morelli, M. P.
    Negrao, M. V.
    Jazaeri, A.
    Johnson, B.
    Kebriaei, P.
    Deniger, D.
    Collinson-Pautz, M.
    Demars, N.
    Heymach, J.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S897 - S897
  • [37] Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients
    T Doi
    H Takiuchi
    A Ohtsu
    N Fuse
    M Goto
    M Yoshida
    N Dote
    Y Kuze
    F Jinno
    M Fujimoto
    T Takubo
    N Nakayama
    R Tsutsumi
    British Journal of Cancer, 2012, 106 : 666 - 672
  • [38] A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.
    Gallagher, Peter F.
    Naylor, Gregory
    Bashir, Saira
    Yan, Xiangfei
    Burke, David
    Plummer, Elizabeth Ruth
    Evans, T. R. Jeffry
    Coyle, Victoria M.
    Clive, Sally
    McGuigan, Lesley
    Heinzmann, Kathrin
    Halbert, Gavin
    Veal, Gareth
    Tiplady, Eleanor
    Barnett, Shelby
    Yalla, Krishna
    Brook, Sue
    Dobbs, Nicola
    Wilson, Richard H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients
    Doi, T.
    Takiuchi, H.
    Ohtsu, A.
    Fuse, N.
    Goto, M.
    Yoshida, M.
    Dote, N.
    Kuze, Y.
    Jinno, F.
    Fujimoto, M.
    Takubo, T.
    Nakayama, N.
    Tsutsumi, R.
    BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 666 - 672
  • [40] A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours
    Vidal, Laura
    Victoria, Ivan
    Gaba, Lydia
    Martin, Marta Gil
    Brunet, Merce
    Colom, Helena
    Cortal, Marc
    Gomez-Ferreria, Mariana
    Yeste-Velasco, Marc
    Perez, Antonio
    Rodon, Jordi
    Sohal, Davendra P. S.
    Lizcano, Jose Miguel
    Domenech, Carles
    Alfon, Jose
    Gascon, Pere
    EUROPEAN JOURNAL OF CANCER, 2021, 146 : 87 - 94
12345